Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Executive leak continues at AZ as another head jumps ship

James Ward-Lilley will become CEO of lung drug specialist Vectura

- PMLiVE

US expands recommended use of meningitis B vaccines

Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba

- PMLiVE

NICE recommends infliximab biosimilars ahead of Remicade

Newly-acquired Hospira and Napp see their infliximab products backed by the HTA body

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

AZ escapes censure over cancer tweet

Firm did not breach UK’s Code of Practice over survival statistics post

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

New health ministers and re-appointments after reshuffle

Industry sees both continuity and change after the UK’s General Election

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links